Theme
Protecting the Gut: Tegoprazan Proves Highly Effective in Preventing NSAID-Induced Peptic Ulcers
Proven Non-Inferiority
Tegoprazan (25 mg) successfully matched the standard treatment, Lansoprazole (15 mg), in preventing gastroduodenal ulcers over 24 weeks of continuous NSAID therapy p=0.0004
The Clinical Challenge & Trial Design
Long-term NSAID use significantly increases the risk of peptic ulcers. A robust, multicenter Phase III double-blind trial was conducted to evaluate the gastroprotective efficacy of Tegoprazan versus Lansoprazole.
Safety & Tolerability
Safety outcomes demonstrated excellent tolerance. Adverse reactions and serious events were comparable between groups.
| Safety Metric | Tegoprazan 25mg | Lansoprazole 15mg |
|---|---|---|
| Adverse Drug Reactions | Comparable | Comparable |
| Serious Adverse Events | Comparable | Comparable |
Primary Efficacy & Symptom Relief
While providing equivalent ulcer prevention at 24 weeks, Tegoprazan delivered significantly superior heartburn relief by week 12 p=0.0421
Recommendation
Tegoprazan is a clinically effective, safe, and well-tolerated alternative gastroprotective therapy for patients requiring continuous, long-term NSAID treatment, offering the distinct added benefit of improved mid-term heartburn relief.